Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

10.8%

4 terminated/withdrawn out of 37 trials

Success Rate

88.6%

+2.1% vs industry average

Late-Stage Pipeline

24%

9 trials in Phase 3/4

Results Transparency

45%

14 of 31 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 2
16(43.2%)
Phase 1
12(32.4%)
Phase 3
9(24.3%)
37Total
Phase 2(16)
Phase 1(12)
Phase 3(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (37)

Showing 20 of 37 trials
NCT01630733Phase 3Completed

A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Role: lead

NCT07392125Phase 3Not Yet Recruiting

Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes

Role: lead

NCT04576949Phase 3Completed

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

Role: lead

NCT05431387Phase 2Completed

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

Role: lead

NCT05206370Phase 3Completed

A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

Role: lead

NCT06435221Phase 3Completed

Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers

Role: lead

NCT05631938Phase 1Completed

Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose

Role: lead

NCT05981768Phase 1Completed

Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers

Role: lead

NCT05566288Phase 1Completed

Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers

Role: lead

NCT01780545Phase 2Completed

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Role: collaborator

NCT01681433Phase 2Terminated

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Role: collaborator

NCT03848208Phase 1Completed

A Single Dose-escalation Study of Cytisine in Adult Smokers

Role: lead

NCT03709823Phase 2Completed

Trial of Cytisine in Adult Smokers

Role: lead

NCT03303911Phase 1Terminated

A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

Role: lead

NCT03509948Phase 1Completed

A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation

Role: lead

NCT03268343Phase 1Completed

A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine

Role: lead

NCT01120470Phase 2Completed

OGX-427 in Castration Resistant Prostate Cancer Patients

Role: collaborator

NCT01829113Phase 2Completed

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

Role: collaborator

NCT02423590Phase 2Unknown

Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers

Role: collaborator

NCT01844817Phase 2Completed

Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer

Role: collaborator